Seattle Genetics Highlights Data from SGN-CD19A Antibody-Drug Conjugate Program at #ASH2015

By: via Benzinga
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A) ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.